Reports
Reports
Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.
The global antiplatelet drugs market is expected to grow at a CAGR of 7% in the forecast period of 2023-2028.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
North America is the leading region in the global market for antiplatelet drugs. The region accounts for a significant share in the industry owing to the increasing penetration of key players in the region and the growing investments in clinical trials for antiplatelet drugs. Further, the presence of a large number of patients suffering from myocardial infarction and ischaemic strokes across the region is also aiding the industry growth. In the United States, around 800,000 individuals suffer from stroke every year, out of which 87% are ischaemic strokes. Thus, the growing prevalence of these diseases is leading to an increased demand for antiplatelet drugs. Meanwhile, the Asia Pacific is expected to witness a robust growth over the forecast period owing to the rising investments in R&D activities and the increasing government initiatives to reduce the number of deaths caused by thrombotic cardiovascular disease.
Antiplatelet drug belongs to a class of pharmaceuticals that decrease platelet aggregation, thus, preventing the formation of thrombus. These drugs are often referred to as platelet aggregation inhibitors. They help prevent blood cells (platelets) from clumping together to form a clot, thereby, decreasing the formation of potentially harmful blood clots. They show high efficacy in the arterial circulation, where anticoagulants are less effective. Antiplatelet drugs are most commonly used in primary and secondary prevention of thrombotic cerebrovascular or cardiovascular disorder.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
By drug, the market is divided into:
On the basis of drug class, the industry can be segmented into:
Based on applications, the industry can be categorised into:
The different routes of administration of antiplatelet drugs are:
The various distribution channels of the product are:
The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The global market for antiplatelet drugs is being driven by the advancements in the pharmaceutical industry and the increasing cases of thrombosis, both arterial and venous. The incidences of venous thrombosis have escalated rapidly in the twenty-first century. Further, in patients with certain medical conditions, prevention and treatment of arterial thrombosis is particularly essential, as it can increase the chances of thrombosis or thromboembolism, which may lead to heart attack, pulmonary embolism, or stroke. Treatment of established arterial thrombosis involves the utilisation of antiplatelet drugs and thrombolytic therapy. These drugs are also essential for an individual who has undergone a heart surgery (especially prosthetic replacement heart valve). Thus, an increase in the number of patients undergoing heart surgery is also aiding the market growth. Other factors like increasing sedentary lifestyles, the proliferation of anticoagulant/antithrombotic drugs, rising geriatric population, and favourable government initiatives are further propelling the industry forward. Over the forecast period, the increasing R&D activities are expected to further contribute to the industry growth.
The report gives a detailed analysis of the following key players in the global antiplatelet drugs market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
REPORT FEATURES | DETAILS |
---|---|
Base Year | 2022 |
Historical Period | 2018-2022 |
Forecast Period | 2023-2028 |
Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Drug, Drug Class, Application, Route of Administration, Distributional Channel, Region |
Breakup by Drug | Aspirin, Clopidogrel, Ticagrelor, Prasugrel, Dipyridamole, Ticlopidine, Abciximab, Tirofiban, Others |
Breakup by Drug Class | Platelet Aggregation Inhibitors, Glycoprotein Platelet Inhibitors, Protease-Activated Receptor-1 Antagonists, Others |
Breakup by Application | Myocardial Infraction, Percutaneous Coronary Interventions, Angioplasty, Arterial Thrombosis, Dental Surgeries, Others |
Breakup by Route of Administration | Oral, Injectable |
Breakup by Distributional Channel | Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others |
Breakup by Region | North America, Latin America, Europe, Middle East and Africa, Asia Pacific |
Market Dynamics | SWOT, Porter's Five Forces, Key Indicators for Price and Demand |
Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
Companies Covered | Glenmark Pharmaceuticals Ltd., Sanofi SA, Pfizer Inc., Baxter International Inc., Bayer AG, Others |
Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Opportunities and Challenges in the Market
8 Global Antiplatelet Drugs Market Analysis
8.1 Key Industry Highlights
8.2 Global Antiplatelet Drugs Historical Market (2018-2022)
8.3 Global Antiplatelet Drugs Market Forecast (2023-2028)
8.4 Global Antiplatelet Drugs Market by Drug
8.4.1 Aspirin
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2018-2022)
8.4.1.3 Forecast Trend (2023-2028)
8.4.2 Clopidogrel
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2018-2022)
8.4.2.3 Forecast Trend (2023-2028)
8.4.3 Ticagrelor
8.4.3.1 Market Share
8.4.3.2 Historical Trend (2018-2022)
8.4.3.3 Forecast Trend (2023-2028)
8.4.4 Prasugrel
8.4.4.1 Market Share
8.4.4.2 Historical Trend (2018-2022)
8.4.4.3 Forecast Trend (2023-2028)
8.4.5 Dipyridamole
8.4.5.1 Market Share
8.4.5.2 Historical Trend (2018-2022)
8.4.5.3 Forecast Trend (2023-2028)
8.4.6 Ticlopidine
8.4.6.1 Market Share
8.4.6.2 Historical Trend (2018-2022)
8.4.6.3 Forecast Trend (2023-2028)
8.4.7 Abciximab
8.4.7.1 Market Share
8.4.7.2 Historical Trend (2018-2022)
8.4.7.3 Forecast Trend (2023-2028)
8.4.8 Tirofiban
8.4.8.1 Market Share
8.4.8.2 Historical Trend (2018-2022)
8.4.8.3 Forecast Trend (2023-2028)
8.4.9 Others
8.5 Global Antiplatelet Drugs Market by Drug Class
8.5.1 Platelet Aggregation Inhibitors
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2018-2022)
8.5.1.3 Forecast Trend (2023-2028)
8.5.2 Glycoprotein Platelet Inhibitors
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2018-2022)
8.5.2.3 Forecast Trend (2023-2028)
8.5.3 Protease-Activated Receptor-1 Antagonists
8.5.3.1 Market Share
8.5.3.2 Historical Trend (2018-2022)
8.5.3.3 Forecast Trend (2023-2028)
8.5.4 Others
8.6 Global Antiplatelet Drugs Market by Application
8.6.1 Myocardial Infraction
8.6.1.1 Market Share
8.6.1.2 Historical Trend (2018-2022)
8.6.1.3 Forecast Trend (2023-2028)
8.6.2 Percutaneous Coronary Interventions
8.6.2.1 Market Share
8.6.2.2 Historical Trend (2018-2022)
8.6.2.3 Forecast Trend (2023-2028)
8.6.3 Angioplasty
8.6.3.1 Market Share
8.6.3.2 Historical Trend (2018-2022)
8.6.3.3 Forecast Trend (2023-2028)
8.6.4 Arterial Thrombosis
8.6.4.1 Market Share
8.6.4.2 Historical Trend (2018-2022)
8.6.4.3 Forecast Trend (2023-2028)
8.6.5 Dental Surgeries
8.6.5.1 Market Share
8.6.5.2 Historical Trend (2018-2022)
8.6.5.3 Forecast Trend (2023-2028)
8.6.6 Others
8.7 Global Antiplatelet Drugs Market by Route of Administration
8.7.1 Oral
8.7.1.1 Market Share
8.7.1.2 Historical Trend (2018-2022)
8.7.1.3 Forecast Trend (2023-2028)
8.7.2 Injectable
8.7.2.1 Market Share
8.7.2.2 Historical Trend (2018-2022)
8.7.2.3 Forecast Trend (2023-2028)
8.8 Global Antiplatelet Drugs Market by Distributional Channel
8.8.1 Hospital Pharmacy
8.8.1.1 Market Share
8.8.1.2 Historical Trend (2018-2022)
8.8.1.3 Forecast Trend (2023-2028)
8.8.2 Retail Pharmacy
8.8.2.1 Market Share
8.8.2.2 Historical Trend (2018-2022)
8.8.2.3 Forecast Trend (2023-2028)
8.8.3 Online Pharmacy
8.8.3.1 Market Share
8.8.3.2 Historical Trend (2018-2022)
8.8.3.3 Forecast Trend (2023-2028)
8.8.4 Others
8.9 Global Antiplatelet Drugs Market by Region
8.9.1 North America
8.9.1.1 Market Share
8.9.1.2 Historical Trend (2018-2022)
8.9.1.3 Forecast Trend (2023-2028)
8.9.2 Europe
8.9.2.1 Market Share
8.9.2.2 Historical Trend (2018-2022)
8.9.2.3 Forecast Trend (2023-2028)
8.9.3 Asia Pacific
8.9.3.1 Market Share
8.9.3.2 Historical Trend (2018-2022)
8.9.3.3 Forecast Trend (2023-2028)
8.9.4 Latin America
8.9.4.1 Market Share
8.9.4.2 Historical Trend (2018-2022)
8.9.4.3 Forecast Trend (2023-2028)
8.9.5 Middle East and Africa
8.9.5.1 Market Share
8.9.5.2 Historical Trend (2018-2022)
8.9.5.3 Forecast Trend (2023-2028)
9 North America Antiplatelet Drugs Market Analysis
9.1 United States of America
9.1.1 Market Share
9.1.2 Historical Trend (2018-2022)
9.1.3 Forecast Trend (2023-2028)
9.2 Canada
9.2.1 Market Share
9.2.2 Historical Trend (2018-2022)
9.2.3 Forecast Trend (2023-2028)
10 Europe Antiplatelet Drugs Market Analysis
10.1 United Kingdom
10.1.1 Market Share
10.1.2 Historical Trend (2018-2022)
10.1.3 Forecast Trend (2023-2028)
10.2 Germany
10.2.1 Market Share
10.2.2 Historical Trend (2018-2022)
10.2.3 Forecast Trend (2023-2028)
10.3 France
10.3.1 Market Share
10.3.2 Historical Trend (2018-2022)
10.3.3 Forecast Trend (2023-2028)
10.4 Italy
10.4.1 Market Share
10.4.2 Historical Trend (2018-2022)
10.4.3 Forecast Trend (2023-2028)
10.5 Others
11 Asia Pacific Antiplatelet Drugs Market Analysis
11.1 China
11.1.1 Market Share
11.1.2 Historical Trend (2018-2022)
11.1.3 Forecast Trend (2023-2028)
11.2 Japan
11.2.1 Market Share
11.2.2 Historical Trend (2018-2022)
11.2.3 Forecast Trend (2023-2028)
11.3 India
11.3.1 Market Share
11.3.2 Historical Trend (2018-2022)
11.3.3 Forecast Trend (2023-2028)
11.4 ASEAN
11.4.1 Market Share
11.4.2 Historical Trend (2018-2022)
11.4.3 Forecast Trend (2023-2028)
11.5 Australia
11.5.1 Market Share
11.5.2 Historical Trend (2018-2022)
11.5.3 Forecast Trend (2023-2028)
11.6 Others
12 Latin America Antiplatelet Drugs Market Analysis
12.1 Brazil
12.1.1 Market Share
12.1.2 Historical Trend (2018-2022)
12.1.3 Forecast Trend (2023-2028)
12.2 Argentina
12.2.1 Market Share
12.2.2 Historical Trend (2018-2022)
12.2.3 Forecast Trend (2023-2028)
12.3 Mexico
12.3.1 Market Share
12.3.2 Historical Trend (2018-2022)
12.3.3 Forecast Trend (2023-2028)
12.4 Others
13 Middle East and Africa Antiplatelet Drugs Market Analysis
13.1 Saudi Arabia
13.1.1 Market Share
13.1.2 Historical Trend (2018-2022)
13.1.3 Forecast Trend (2023-2028)
13.2 United Arab Emirates
13.2.1 Market Share
13.2.2 Historical Trend (2018-2022)
13.2.3 Forecast Trend (2023-2028)
13.3 Nigeria
13.3.1 Market Share
13.3.2 Historical Trend (2018-2022)
13.3.3 Forecast Trend (2023-2028)
13.4 South Africa
13.4.1 Market Share
13.4.2 Historical Trend (2018-2022)
13.4.3 Forecast Trend (2023-2028)
13.5 Others
14 Market Dynamics
14.1 SWOT Analysis
14.1.1 Strengths
14.1.2 Weaknesses
14.1.3 Opportunities
14.1.4 Threats
14.2 Porter’s Five Forces Analysis
14.2.1 Supplier’s Power
14.2.2 Buyer’s Power
14.2.3 Threat of New Entrants
14.2.4 Degree of Rivalry
14.2.5 Threat of Substitutes
14.3 Key Indicators for Demand
14.4 Key Indicators for Price
15 Value Chain Analysis
16 Competitive Landscape
16.1 Market Structure
16.2 Company Profiles
16.2.1 Glenmark Pharmaceuticals Ltd.
16.2.1.1 Company Overview
16.2.1.2 Product Portfolio
16.2.1.3 Demographic Reach and Achievements
16.2.1.4 Certifications
16.2.2 Sanofi SA
16.2.2.1 Company Overview
16.2.2.2 Product Portfolio
16.2.2.3 Demographic Reach and Achievements
16.2.2.4 Certifications
16.2.3 Pfizer Inc.
16.2.3.1 Company Overview
16.2.3.2 Product Portfolio
16.2.3.3 Demographic Reach and Achievements
16.2.3.4 Certifications
16.2.4 Baxter International Inc.
16.2.4.1 Company Overview
16.2.4.2 Product Portfolio
16.2.4.3 Demographic Reach and Achievements
16.2.4.4 Certifications
16.2.5 Bayer AG
16.2.5.1 Company Overview
16.2.5.2 Product Portfolio
16.2.5.3 Demographic Reach and Achievements
16.2.5.4 Certifications
16.2.6 Others
17 Key Trends and Developments in the Market
List of Key Figures and Tables
1. Global Antiplatelet Drugs Market: Key Industry Highlights, 2018 and 2028
2. Global Antiplatelet Drugs Historical Market: Breakup by Drug (USD Million), 2018-2022
3. Global Antiplatelet Drugs Market Forecast: Breakup by Drug (USD Million), 2023-2028
4. Global Antiplatelet Drugs Historical Market: Breakup by Drug Class (USD Million), 2018-2022
5. Global Antiplatelet Drugs Market Forecast: Breakup by Drug Class (USD Million), 2023-2028
6. Global Antiplatelet Drugs Historical Market: Breakup by Application (USD Million), 2018-2022
7. Global Antiplatelet Drugs Market Forecast: Breakup by Application (USD Million), 2023-2028
8. Global Antiplatelet Drugs Historical Market: Breakup by Distributional Channel (USD Million), 2018-2022
9. Global Antiplatelet Drugs Market Forecast: Breakup by Distributional Channel (USD Million), 2023-2028
10. Global Antiplatelet Drugs Historical Market: Breakup by Region (USD Million), 2018-2022
11. Global Antiplatelet Drugs Market Forecast: Breakup by Region (USD Million), 2023-2028
12. North America Antiplatelet Drugs Historical Market: Breakup by Country (USD Million), 2018-2022
13. North America Antiplatelet Drugs Market Forecast: Breakup by Country (USD Million), 2023-2028
14. Europe Antiplatelet Drugs Historical Market: Breakup by Country (USD Million), 2018-2022
15. Europe Antiplatelet Drugs Market Forecast: Breakup by Country (USD Million), 2023-2028
16. Asia Pacific Antiplatelet Drugs Historical Market: Breakup by Country (USD Million), 2018-2022
17. Asia Pacific Antiplatelet Drugs Market Forecast: Breakup by Country (USD Million), 2023-2028
18. Latin America Antiplatelet Drugs Historical Market: Breakup by Country (USD Million), 2018-2022
19. Latin America Antiplatelet Drugs Market Forecast: Breakup by Country (USD Million), 2023-2028
20. Middle East and Africa Antiplatelet Drugs Historical Market: Breakup by Country (USD Million), 2018-2022
21. Middle East and Africa Antiplatelet Drugs Market Forecast: Breakup by Country (USD Million), 2023-2028
22. Global Antiplatelet Drugs Market Structure
The global antiplatelet drugs market is projected to grow at a CAGR of 7% between 2021 and 2026.
The major drivers of the industry, such as the advancements in the pharmaceutical sector, increasing prevalence of thrombotic cardiovascular disease, increasing geriatric population, proliferation of anticoagulant/antithrombotic drugs, favourable government initiatives, and busy lifestyles, are expected to aid the market growth.
The key market trends guiding the growth of the industry include the growing investments by the key players in the research and development of antiplatelet drugs.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The leading drugs in the market are aspirin, clopidogrel, ticagrelor, prasugrel, dipyridamole, ticlopidine, abciximab, and tirofiban, among others.
The major drug classes in the industry are platelet aggregation inhibitors, glycoprotein platelet inhibitors, and protease-activated receptor-1 antagonists, among others.
The significant application segments in the market are myocardial infraction, percutaneous coronary interventions, angioplasty, arterial thrombosis, and dental surgeries, among others.
The leading routes of administration of antiplatelet drugs in the industry are oral and injectable.
The major distribution channels in the market are hospital pharmacy, retail pharmacy, and online pharmacy, among others.
The major players in the industry are Glenmark Pharmaceuticals Ltd., Sanofi SA, Pfizer Inc., Baxter International Inc., and Bayer AG, among others.
The global antiplatelet drugs market is being driven by the rising prevalence of thrombotic cardiovascular disease. Aided by the favourable government initiatives , the market is expected to witness a healthy growth in the forecast period of 2023-2028, growing at a CAGR of 7%.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on drug, the market is segmented into aspirin, clopidogrel, ticagrelor, prasugrel, dipyridamole, ticlopidine, abciximab, and tirofiban, among others. By drug class, the industry is divided into platelet aggregation inhibitors, glycoprotein platelet inhibitors, and protease-activated receptor-1 antagonists, among others. On the basis of applications, the market is categorised into myocardial infraction, percutaneous coronary interventions, angioplasty, arterial thrombosis, and dental surgeries, among others. Based on routes of administration, the industry is segmented into oral and injectable. By distribution channels, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy, among others. The major regional markets for antiplatelet drugs are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include Glenmark Pharmaceuticals Ltd., Sanofi SA, Pfizer Inc., Baxter International Inc., and Bayer AG, among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.